Razelle Kurzrock, Founding Director at Michels Rare Cancers Research Laboratories, shared Vivek Subbiah’s, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, post on LinkedIn, adding:
“Pleasure to publish with Vivek Subbiah.
Guidelines should not limit sarcoma access to full diagnosis including NGS.
Many USA pts may not be able to travel to specialist. NGS access should be equitable.
Also Annals of Oncology now has impact factor of 80. Well deserved.”
Quoting Vivek Subbiah’s post:
“Hot off the press – Pre-proof vesion.
Pleased to share our Editorial in European Society for Medical Oncology (ESMO) flagship journal Annals of Oncology.
‘Next-Generation Sequencing Consensus Guidelines for Sarcoma: Progress, Gaps, and the Path Forward’
Razelle Kurzrock and I opine that ‘Consensus must accelerate our field, not delay it. For many sarcomas, genomics isn’t ancillary, it Is the Diagnosis’.
Huge congrats to Annals of Oncology for its exceptional leadership in the field standing as one of oncology’s most highly cited journals (IF 80+).”
Title: Next-Generation Sequencing Consensus Guidelines for Sarcoma: Progress, Gaps, and the Path Forward
Authors: V. Subbiah, R. Kurzrock
Other articles featuring Razelle Kurzrock and Vivek Subbiah on OncoDaily.